Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | SCD | O00767 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.45 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.43 |
| ▸ | PDE9A | O76083 | 3/20 | 0.43 |
| ▸ | PDE1A | P54750 | 3/20 | 0.43 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31195616 | 1.00 | PDE10A (0.49) | PDE10ADDB1CRBNMAPK1SCD | |
| Hydrochloric Acid SCHEMBL18399330 | 0.98 | PDE10A (0.48) | PDE10ADDB1CRBNMAPK1SCD | |
| Hydrochloric Acid SCHEMBL18399296 | 0.89 | DDB1 (0.44) | PDE10ADDB1CRBNMAPK1SCD | |
| SCHEMBL17404486 | 0.88 | DDB1 (0.53) | PDE10ADDB1CRBNSCDPDE9A | |
| SCHEMBL31495775 | 0.84 | DDB1 (0.50) | PDE10ADDB1CRBNSCDPDE1C | |
| SCHEMBL29303151 | 0.84 | DDB1 (0.50) | PDE10ADDB1CRBNSCDPDE1C | |
| SCHEMBL30821940 | 0.83 | DDB1 (0.46) | PDE10ADDB1CRBNSCDPDE1C | |
| SCHEMBL29152986 | 0.83 | DDB1 (0.49) | PDE10ADDB1CRBNSCDPDE1C | |
| SCHEMBL29303028 | 0.83 | DDB1 (0.46) | PDE10ADDB1CRBNSCDPDE1C | |
| SCHEMBL15440769 | 0.81 | DDB1 (0.43) | PDE10ADDB1CRBNSCDPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | PIM1, PIM2, PIM3 | PDE10A 2326/4885DDB1 1455/4885CRBN 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.